Author(s): Toni K. Choueiri, M.D., Piotr Tomczak, M.D., Ph.D., Se Hoon Park, M.D., Balaji Venugopal, M.D., Tom Ferguson, M.D., Stefan N. Symeonides, M.D., Ph.D., Jaroslav Hajek, M.U.Dr., Yen-Hwa Chang, M.D., Ph.D., Jae-Lyun Lee, M.D., Ph.D., Naveed Sarwar, M.D., Ph.D., Naomi B. Haas, M.D., Howard Gurney, M.B., B.S., Piotr Sawrycki, M.D., Mauricio Mahave, M.D., Marine Gross-Goupil, M.D., Ph.D., Tian Zhang, M.D., John M. Burke, M.D., Gurjyot Doshi, M.D., Bohuslav Melichar, M.D., Evgeniy Kopyltsov, M.D., Ajjai Alva, M.D., Stephane Oudard, M.D., Delphine Topart, M.D., Hans Hammers, M.D., Ph.D., Hiroshi Kitamura, M.D., Ph.D., David F. McDermott, M.D., Adriano Silva, M.D., Eric Winquist, M.D., Jerry Cornell, Ph.D., Aymen Elfiky, M.D., Joseph E. Burgents, Ph.D., Rodolfo F. Perini, M.D., and Thomas Powles, M.D., for the KEYNOTE-564 Investigators*
Author Affiliations
From Dana–Farber Cancer Institute and Harvard Medical School (T.K.C.) and Beth Israel Deaconess Medical Center (D.F.M.) — all in Boston; Poznan University of Medical Sciences, Poznan (P.T.), and Provincial Hospital in Torun, Torun (P.S.) — both in Poland; Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Asan Medical Center, University of Ulsan College of Medicine (J.-L.L.) — both in Seoul, South Korea; Beatson West of Scotland Cancer Centre and the University of Glasgow, Glasgow (B.V.), Edinburgh Cancer Centre and the University of Edinburgh, Edinburgh (S.N.S.), and Imperial College Healthcare NHS Trust (N.S.), Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute (T.P.), and Queen Mary University of London (T.P.), London — all in the United Kingdom; Fiona Stanley Hospital, Perth, WA (T.F.), and Maquarie University, Sydney (H.G.) — both in Australia; Fakultní Nemocnice Ostrava, Ostrava (J.H.), and Palacký University and University Hospital Olomouc, Olomouc (B.M.) — all in the Czech Republic; Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Abramson Cancer Center, Penn Medicine, Philadelphia (N.B.H.); Fundación Arturo López Pérez, Santiago, Chile (M.M.); University Hospital Bordeaux–Hôpital Saint-André, Bordeaux (M.G.-G.), Hôpital Européen Georges Pompidou, Université Paris Cité, Paris (S.O.), and Centre Hospitalier Universitaire de Montpellier, Montpellier (D.T.) — all in France; the University of Texas Southwestern Medical Center, Dallas (T.Z., H.H.), and Texas Oncology–Houston, Houston (G.D.); Rocky Mountain Cancer Centers, Aurora, CO (J.M.B.); Omsk Clinical Oncology Dispensary, Omsk, Russia (E.K.); the University of Michigan, Ann Arbor (A.A.); the University of Toyama, Toyama, Japan (H.K.); Instituto de Cancer e Transplante de Curitiba, Curitiba, Brazil (A.S.); the London Regional Cancer Program, London Health Sciences Centre, Western University, London, ON, Canada (E.W.); and Merck, Rahway, NJ (J.C., A.E., J.E.B., R.F.P.).